COVID19 Acute respiratory distress syndrome and extra-corporeal membrane oxygenation; A mere option or ultimate necessity
- PMID: 33008270
- DOI: 10.1177/0267659120961507
COVID19 Acute respiratory distress syndrome and extra-corporeal membrane oxygenation; A mere option or ultimate necessity
Abstract
Extracorporeal membrane oxygenation (ECMO) is considered a salvage therapy in patients with acute respiratory distress syndrome (ARDS) and refractory hypoxemia (hypoxemia persisting despite lung-protective ventilation). One aspect of ECMO is whether there would be an application of the technology related to the Coronavirus pandemic. The number of people diagnosed with Coronavirus disease (COVID19) has crossed the five million mark on 9 August 2020, with a case fatality rate of 5.2%. Due to this exponential increase in the number of coronavirus disease (COVID19) cases particularly the ones associated with ARDS, experts are evaluating the need for ECMO in intensive care units. Herein, we chronicle a review encompassing the available evidence on ECMO and its potential role in COVID19 ARDS, as we aim for optimal patient care with appropriate resource utilization and conservation.
Keywords: COVID-19; ECMO; VV-ECMO; acute respiratory distress syndrome; extracorporeal membrane oxygenation.
Comment in
-
Selecting candidates for veno-venous ECMO during COVID-19 pandemic: the importance of an ECMO team.Perfusion. 2021 Sep;36(6):640-642. doi: 10.1177/02676591211005705. Epub 2021 Mar 24. Perfusion. 2021. PMID: 33759648 No abstract available.